BioLife Sciences Inc.
BLFE · OTC
11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 418.57 | 8.99 | -0.45 |
| FCF Yield | -1.51% | 0.00% | -0.03% | -0.18% |
| EV / EBITDA | -48.15 | 265.96 | -1,084.30 | -32.18 |
| Quality | ||||
| ROIC | 248.80% | 0.00% | 53.74% | 775.89% |
| Gross Margin | -239.25% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | -0.01 | 0.24 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -5,207,564.71% | 100.14% | 32.82% | -62.01% |
| Safety | ||||
| Net Debt / EBITDA | -0.13 | -0.00 | -3.33 | -0.39 |
| Interest Coverage | -25.22 | 0.00 | -4.05 | -29.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -128.82 | 0.00 | 0.00 | 0.00 |